Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer

Here are answers to 10 questions patients asked at the CURE® Educated Patient® Metastatic Breast Cancer Summit about scans, treatment and clinical trials.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

My wife faced ovarian cancer, breast cancer and multifocal motor neuropathy, and I was her only caregiver.

CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.

Having my omentum removed after an ovarian cancer diagnosis impacted my quality of life.

Before enrolling in a clinical trial for metastatic breast cancer, it’s important to know which are best suited for each individual, an expert said.